Stay updated with breaking news from Mark Swallow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EO2401 is a first-in-class OncoMimics therapeutic cancer vaccine able to significantly expand existing effector memory CD8+ T cells directed at OncoMimics peptides corresponding to tumor-associated
/PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central...
Enterome is evaluating EO2401 in Phase 1/2 clinical trials in recurrent glioblastoma (ROSALIE) and adrenocortical malignancies (SPENCER) Proof-of-concept data...
Enterome is evaluating EO2401 in Phase 1/2 clinical trials in recurrent glioblastoma (ROSALIE) and adrenocortical malignancies (SPENCER)Proof-of-concept data in both trials of EO2401 have demonstrated
Enterome and Nestlé Health Science will co-develop Enterome's lead EndoMimics compound, EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD).